- Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy<figure><div><img src="https://imgproxy.divecdn.com/Sl1QCaU_supqAvtEJA_tXhY8sXexPvdgos3TT-jjIM4/g:ce/rs:fill:1600:900:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9HZXR0eUltYWdlcy0xMjA1MzM4Nzg3LmpwZ…BioPharma Dive · 1mo ago↗ source
- STAT+: A suspicious denial pattern in Medicare AdvantageMajor Medicare Advantage plans almost always reversed their denials on appeal, raising big questions about barriers to care.STAT · 1mo ago↗ source
- Novartis RNA drug acquired in $12B Avidity deal notches a trial win<p>The data showed that del-brax, an “antisense oligonucleotide conjugate” being tested against a muscle-wasting disease, met its primary endpoint in a Phase 1/2 study.</p>